Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Veröffentlicht: |
Wiley
2024
|
| Schlagworte: | |
| Online-Zugang: | https://onlinelibrary.wiley.com/doi/10.1002/pbc.31213 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Inhaltsangabe:
- Toxicity profile of high‐dose methotrexate in young children with central nervous system tumors Ashley N. Chavana Zachary L. Taylor Nicholas DeGroote Holly B. Lindsay Hannah E. Sauer Emily J. Mason Eric S. Schafer Tamara P. Miller Sharon M. Castellino Lauren Pommert Maureen M. O'Brien Laura B. Ramsey M. Brooke Bernhardt Austin L. Brown Pediatric Blood & Cancer AbstractHigh‐dose methotrexate (HD‐MTX) is used in the treatment of children with central nervous system (CNS) tumors; however, toxicity information is limited. We characterized toxicities following 102 administrations of HD‐MTX (4.6–13.5 g/m2) infused over 4 or 24 h in 38 children with a CNS tumor before 6 years of age (2010–2020). Delayed clearance of methotrexate occurred following 24% of infusions. Common Terminology Criteria for Adverse Events v5 grade 2–3 mucositis was observed in 47% of individuals, Grade 4 neutropenia in 76%, and grade 3–4 thrombocytopenia in 58%. No neurotoxicity was observed. HD‐MTX can be safely used with supportive care and monitoring. 10.1002/pbc.31213 http://onlinelibrary.wiley.com/termsAndConditions#vor